Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Surgery for Limited SCLC
Author
Howard (Jack) West, MD

Here's the podcast from a webinar I did last month with Dr. Weiss on the subject of whether patients with very limited small cell lung cancer (SCLC) should perhaps undergo surgery as a first intervention. Historically, surgery isn't considered as a typical treatment for patients with SCLC, even if it's very early stage, but some results from retrospective experiences suggest that the patients who undergo surgery in this setting do very well. While that's true, the central question is whether they do well because they receive surgery or because they had a very unusual SCLC that was able to be detected so early. This podcast covers the evidence and the lingering questions about this topic. Along the way, it also provides some discussion of the general characteristics of SCLC.

Here's the audio and video versions of the podcast, along with the figures and transcript for the program.

[powerpress]

west-surgery-for-limited-sclc-audio-podcast

west-surgery-for-limited-sclc-figures

west-surgery-for-limited-sclc-transcript

This doesn't apply to very many people, since it's only a consideration for a minority of patients with SCLC, but the principle of patient selection vs. true value of the intervention in small studies, especially retrospective single institution experiences, is very important in interpreting results of cancer publications.

Next I'll cover some exciting results from a trial of ARQ-197, a c-MET inhibitor that has looked encouraging with Tarceva, and the excellent webinar by Dr. Mark Socinski on maintenance chemotherapy is being completed for posting here very soon as well.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on